PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations

In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June.

Fuente : http://www.eurekalert.org/pub_releases/2013-05/uop...